Lv4
490 积分 2022-11-14 加入
Integration of PSMA-Targeted Theranostics into Multidisciplinary Care for Improved Efficiencies and Patient Care
8天前
已完结
A Deep Prostate-specific Antigen Response to Darolutamide plus Androgen Deprivation Therapy Is Associated with Better Clinical Outcomes in the Phase 3 ARANOTE Trial in Patients with Metastatic Hormone-sensitive Prostate Cancer
11天前
已完结
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
13天前
已完结
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
13天前
已完结
Personalized intensification of treatment for hormone-sensitive prostate cancer
20天前
已完结
P150 Updated Overall Survival (OS) estimates leveraging long term extension data from TITAN study evaluating Apalutamide (APA) versus Placebo (PBO) in metastatic Hormone Sensitive Prostate Cancer (mHSPC) patients
2个月前
已完结
Emerging evidence for sequencing and combining PSMA-based therapies in prostate cancer
2个月前
已完结
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2个月前
已完结
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial
2个月前
已完结
Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies
2个月前
已完结
皖公网安备34019202002308
